Loading financial data...

KalVista Pharmaceuticals, Inc. (KALV) Financial Statements | Global Financial Data

KalVista Pharmaceuticals, Inc.

KALVSEC EDGAR

Pharmaceutical Preparations(DE)CIK: 1348911

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue from Contract with Customer, Excluding Assessed Tax	—	—	—	$12.7M	$16.1M
Research and Development Expense	$86.2M	$70.2M	$41.3M	$40.2M	$35.0M
Operating Expenses	$140.4M	$96.6M	$57.9M	$53.2M	$45.9M
Operating Income (Loss)	-$140.4M	-$96.6M	-$57.9M	-$40.5M	-$29.8M
Interest Expense	—	—	—	—	—
Nonoperating Income (Expense)	$13.8M	$14.3M	$11.7M	$11.3M	$9.1M
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	-$126.6M	-$82.3M	-$46.2M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$235.4M	$183.2M	$203.9M	$272.0M	$92.5M
Assets, Current	$225.7M	$172.3M	$193.6M	$264.3M	$88.7M
Cash and Cash Equivalents, at Carrying Value	$31.8M	$56.2M	$30.7M	$50.6M	$15.8M
Liabilities	—	—	—	—	—
Liabilities, Current	$22.8M	$15.0M	$11.6M	$9.8M	$7.7M
Accounts Payable, Current	$9.1M	$4.8M	$3.6M	$2.0M	$1.7M
Stockholders' Equity Attributable to Parent	$161.0M	$257.2M	$83.8M	$96.7M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$89.2M	-$78.1M	-$30.2M	-$44.8M	-$36.4M
Net Cash Provided by (Used in) Investing Activities	-$84.7M	$57.9M	-$147.7M	$16.8M	-$69.4M
Net Cash Provided by (Used in) Financing Activities	$150.7M	$1.6M	$212.1M	$11.6M	$87.9M
Payments to Acquire Property, Plant, and Equipment	$42.0K	$931.0K	$82.0K	$220.0K	$1.1M

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)